Osivax
Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.
Tech Stack (26 technologies)
Frequently Asked Questions
What technologies does Osivax use?+
Osivax uses 26 technologies including Contact Form 7, Elementor, Google Analytics.
What industry is Osivax in?+
Osivax operates in the Biotechnology industry.
Where is Osivax based?+
Osivax is headquartered in France.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026